NZ548302A - Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases - Google Patents
Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseasesInfo
- Publication number
- NZ548302A NZ548302A NZ548302A NZ54830205A NZ548302A NZ 548302 A NZ548302 A NZ 548302A NZ 548302 A NZ548302 A NZ 548302A NZ 54830205 A NZ54830205 A NZ 54830205A NZ 548302 A NZ548302 A NZ 548302A
- Authority
- NZ
- New Zealand
- Prior art keywords
- use according
- formoteroi
- glycopyrrolate
- daily dose
- salmeterol
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 20
- 208000023504 respiratory system disease Diseases 0.000 title description 11
- 230000001078 anti-cholinergic effect Effects 0.000 title description 6
- 239000000808 adrenergic beta-agonist Substances 0.000 title 1
- 230000003454 betamimetic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960004017 salmeterol Drugs 0.000 claims abstract description 14
- 208000006673 asthma Diseases 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 22
- 239000000443 aerosol Substances 0.000 claims description 9
- 239000003380 propellant Substances 0.000 claims description 8
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 claims description 7
- 239000000150 Sympathomimetic Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- -1 adjuncts Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000001975 sympathomimetic effect Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims 4
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229940085605 saccharin sodium Drugs 0.000 claims 1
- 229940117972 triolein Drugs 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 abstract description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 20
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 206010006482 Bronchospasm Diseases 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 230000000414 obstructive effect Effects 0.000 description 7
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000007885 bronchoconstriction Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000005923 long-lasting effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 208000000884 Airway Obstruction Diseases 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000003182 bronchodilatating effect Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 102000017925 CHRM3 Human genes 0.000 description 2
- 101150060249 CHRM3 gene Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000000572 bronchospasmolytic effect Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 229960005018 salmeterol xinafoate Drugs 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- VPNYRYCIDCJBOM-ZFNKBKEPSA-M [(3r)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](C)(C)CC[C@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-ZFNKBKEPSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000682 bronchomotor Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 108700025647 major vault Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195704P | 2004-02-06 | 2004-02-06 | |
| PCT/EP2005/000649 WO2005074900A2 (en) | 2004-02-06 | 2005-01-24 | NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ548302A true NZ548302A (en) | 2010-04-30 |
Family
ID=34837534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ548302A NZ548302A (en) | 2004-02-06 | 2005-01-24 | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20050175549A1 (enExample) |
| EP (1) | EP1718336B1 (enExample) |
| JP (1) | JP5524442B2 (enExample) |
| CN (1) | CN1905902A (enExample) |
| AT (1) | ATE399027T1 (enExample) |
| AU (1) | AU2005210083B2 (enExample) |
| CA (1) | CA2550841C (enExample) |
| CY (1) | CY1108326T1 (enExample) |
| DE (1) | DE602005007708D1 (enExample) |
| DK (1) | DK1718336T3 (enExample) |
| ES (1) | ES2309705T3 (enExample) |
| HR (1) | HRP20080439T3 (enExample) |
| NO (1) | NO337128B1 (enExample) |
| NZ (1) | NZ548302A (enExample) |
| PL (1) | PL1718336T3 (enExample) |
| PT (1) | PT1718336E (enExample) |
| RU (1) | RU2438660C2 (enExample) |
| SI (1) | SI1718336T1 (enExample) |
| WO (1) | WO2005074900A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4369C1 (ro) * | 2011-03-04 | 2016-04-30 | Sosei R&D Ltd | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| NZ548300A (en) * | 2004-02-06 | 2010-04-30 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD |
| GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| ES2389231T3 (es) * | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
| US20080031828A1 (en) * | 2006-08-03 | 2008-02-07 | Boehringer Ingelheim International Gmbh | Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| EP2257172A4 (en) * | 2008-02-26 | 2013-07-03 | Elevation Pharmaceuticals Inc | METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2221048A1 (en) | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| PT3111927T (pt) * | 2009-05-29 | 2020-03-03 | Pearl Therapeutics Inc | Composições para administração respiratória de agentes ativos e métodos e sistemas associados |
| US20110132355A1 (en) * | 2009-06-09 | 2011-06-09 | William Gerhart | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| WO2011076843A2 (en) * | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| ES2467928T3 (es) * | 2009-12-23 | 2014-06-13 | Chiesi Farmaceutici S.P.A. | Formulación en aerosol para EPOC |
| BR112012015334A2 (pt) * | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| GEP20166479B (en) * | 2009-12-23 | 2016-05-25 | Chiesi Farma Spa | Aerosol formulation for copd |
| RU2013142268A (ru) * | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| AU2011368334A1 (en) * | 2011-05-17 | 2013-11-21 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| TR201902687T4 (tr) | 2013-03-15 | 2019-03-21 | Pearl Therapeutics Inc | İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler. |
| MA39154A1 (fr) * | 2013-12-30 | 2017-08-31 | Chiesi Farm Spa | Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol |
| BR112016014583B1 (pt) * | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| WO2017077488A1 (en) * | 2015-11-04 | 2017-05-11 | Glenmark Pharmaceuticals Limited | An inhalable fixed dose powder composition comprising glycopyrronium and formoterol |
| AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000016A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| NZ336202A (en) | 1996-11-11 | 2000-10-27 | Christian R Noe | Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases |
| US6585958B1 (en) | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| CA2338680C (en) * | 1998-08-04 | 2008-10-14 | Jago Research Ag | Medicinal aerosol formulations |
| HU226164B1 (en) * | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| GB0008485D0 (en) * | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
-
2005
- 2005-01-24 HR HR20080439T patent/HRP20080439T3/xx unknown
- 2005-01-24 AU AU2005210083A patent/AU2005210083B2/en not_active Ceased
- 2005-01-24 CA CA2550841A patent/CA2550841C/en not_active Expired - Fee Related
- 2005-01-24 ES ES05701139T patent/ES2309705T3/es not_active Expired - Lifetime
- 2005-01-24 CN CNA2005800019327A patent/CN1905902A/zh active Pending
- 2005-01-24 JP JP2006551761A patent/JP5524442B2/ja not_active Expired - Fee Related
- 2005-01-24 EP EP05701139A patent/EP1718336B1/en not_active Expired - Lifetime
- 2005-01-24 PL PL05701139T patent/PL1718336T3/pl unknown
- 2005-01-24 DK DK05701139T patent/DK1718336T3/da active
- 2005-01-24 WO PCT/EP2005/000649 patent/WO2005074900A2/en not_active Ceased
- 2005-01-24 NZ NZ548302A patent/NZ548302A/en not_active IP Right Cessation
- 2005-01-24 RU RU2006132036/15A patent/RU2438660C2/ru not_active Application Discontinuation
- 2005-01-24 SI SI200530323T patent/SI1718336T1/sl unknown
- 2005-01-24 PT PT05701139T patent/PT1718336E/pt unknown
- 2005-01-24 DE DE602005007708T patent/DE602005007708D1/de not_active Expired - Lifetime
- 2005-01-24 AT AT05701139T patent/ATE399027T1/de active
- 2005-02-07 US US11/051,469 patent/US20050175549A1/en not_active Abandoned
-
2006
- 2006-07-11 US US11/483,693 patent/US20060252815A1/en not_active Abandoned
- 2006-08-31 NO NO20063882A patent/NO337128B1/no not_active IP Right Cessation
-
2007
- 2007-07-30 US US11/882,109 patent/US7985766B2/en active Active
-
2008
- 2008-09-10 CY CY20081100967T patent/CY1108326T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4369C1 (ro) * | 2011-03-04 | 2016-04-30 | Sosei R&D Ltd | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei |
Also Published As
| Publication number | Publication date |
|---|---|
| SI1718336T1 (sl) | 2008-10-31 |
| US7985766B2 (en) | 2011-07-26 |
| AU2005210083A1 (en) | 2005-08-18 |
| AU2005210083B2 (en) | 2010-03-11 |
| EP1718336A2 (en) | 2006-11-08 |
| US20070270481A1 (en) | 2007-11-22 |
| NO20063882L (no) | 2006-10-26 |
| DE602005007708D1 (de) | 2008-08-07 |
| HRP20080439T3 (hr) | 2008-10-31 |
| NO337128B1 (no) | 2016-01-25 |
| ATE399027T1 (de) | 2008-07-15 |
| US20050175549A1 (en) | 2005-08-11 |
| CY1108326T1 (el) | 2014-02-12 |
| WO2005074900A3 (en) | 2006-04-06 |
| CA2550841A1 (en) | 2005-08-18 |
| CN1905902A (zh) | 2007-01-31 |
| PL1718336T3 (pl) | 2008-11-28 |
| PT1718336E (pt) | 2008-08-28 |
| EP1718336B1 (en) | 2008-06-25 |
| JP5524442B2 (ja) | 2014-06-18 |
| DK1718336T3 (da) | 2008-10-20 |
| JP2007520506A (ja) | 2007-07-26 |
| RU2006132036A (ru) | 2008-03-20 |
| RU2438660C2 (ru) | 2012-01-10 |
| ES2309705T3 (es) | 2008-12-16 |
| WO2005074900A2 (en) | 2005-08-18 |
| US20060252815A1 (en) | 2006-11-09 |
| CA2550841C (en) | 2012-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7985766B2 (en) | Combination of anticholineric and β mimetics for the treatment of respiratory diseases | |
| AU2004216472B2 (en) | Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients | |
| SK285884B6 (sk) | Kombinovaný prípravok formoterolu a tiotrópiovej soli, jeho použitie a farmaceutická súprava, ktoráho obsahuje | |
| CN1399540A (zh) | 包含福莫特罗的气雾剂组合物 | |
| CN102724974A (zh) | 毒蕈碱受体拮抗剂和β-2肾上腺素受体激动剂的组合 | |
| US20090181935A1 (en) | Compositions comprising an antimuscarinic and a long-acting beta-agonist | |
| CA2588042A1 (en) | Compositions and methods for pulmonary conditions | |
| CA2420532A1 (en) | Pharmaceutical formulation of salmeterol and fluticasone propionate | |
| AU2008259864A1 (en) | Methods and compositions for administration of Oxybutynin | |
| WO2004084897A1 (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases | |
| JP2014237666A (ja) | アルホルモテロール及びチオトロピウムの組成物及びその使用方法 | |
| Durham | Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease | |
| AU2003292120A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| Op't Holt | Inhaled beta agonists | |
| MXPA06008936A (en) | NOVEL COMBINATION OF ANTICHOLINERGIC AND beta MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| US20060199865A1 (en) | Synergistic combination comprising roflumilast and (r,r) - formoterol | |
| HK1098355A (en) | NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| WO2004084894A1 (en) | Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 24 JAN 2025 BY DENNEMEYER + CO Effective date: 20140823 Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 JAN 2018 BY DENNEMEYER + CO Effective date: 20140822 |
|
| EXPY | Patent expired |